# Onego Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/onego-bio

- Industry: Biotechnology
- Headquarters: Helsinki, Finland
- Website: www.onego.bio/
- Total disclosed funding: $40M
- Latest round: Series A (Mar 31, 2024)
- Investors on record: 7

## About

Based in Helsinki, Finland, and founded in 2022, Onego Bio Ltd operates as a biotechnology company. The company was formed as a spin-off from Finland's VTT Technical Research Centre, when its CEO, Maija Itkonen, and CTO, Christopher Landowski, acquired a technology license from VTT. In 2025, Onego Bio Ltd raised EUR 40 million in venture funding.

Onego Bio develops and produces animal-free egg white protein (bioalbumen) by using precision fermentation, cellular agriculture, and a bioreactor. The company plans to distribute its product as a culinary ingredient to bakeries and confectioneries, as well as a protein supplement to fitness product manufacturers. Later, the company intends to enter the consumer market with its own line of baking and cooking products.

The company plans to use the 2025 funding to build a production facility in Wisconsin for fermentation-based egg-free protein.

## Funding rounds

- Series A, Mar 31, 2024, $29M — Tesi, Maki.vc, NordicNinja VC, Turret, EIT Food iVZW, Agronomics Limited, Holdix
- Seed, Feb 22, 2022, $11M — Maki.vc, Agronomics Limited

## Investors

- Maki.vc (https://capitalatlas.ai/funds/maki-vc) — Seed, Series A
- Agronomics Limited (https://capitalatlas.ai/funds/agronomics-limited) — Seed, Series A
- Tesi (https://capitalatlas.ai/funds/tesi) — Series A
- NordicNinja VC (https://capitalatlas.ai/funds/nordicninja-vc) — Series A
- Turret — Series A
- EIT Food iVZW — Series A
- Holdix — Series A